Embed Size (px)
Citation preview
“TOSERVEPATIENTS”
DYLANSCELZA
ProblemSolved
Pioneersmedicinestoaddressdiseaseswithlimitedtreatmentoptions
Whatisbiotechnology inmedicine?
Whatisbiotechnology inmedicine?
• Mixofbiology,chemistry,andtechnology
Whatisbiotechnology inmedicine?
• Mixofbiology,chemistry,andtechnology• Derivedfromlivingorganisms
Whatisbiotechnology inmedicine?
• Mixofbiology,chemistry,andtechnology• Derivedfromlivingorganisms• Medicinerequiresinjectionorinfusion
CoreProducts
• Enbrel:Targetsautoimmunediseases• Neulasta:Boostswhitebloodcells• Aranesp:Boostsredbloodcells
Financials:(AMGN)
• AnnualRevenue:$23B
• OperatingMargin:48%
• MarketCap:$114B 0
5
10
15
20
25
Revenuein$B
’12’13’14’15’16
YEAR
Financials:(AMGN)
• AnnualRevenue:$23B
• OperatingMargin:48%
• MarketCap:$114B
BusinessModel
• Brandeddrugs• Acquiringpromisingcompanies
• Biosimilars (soon)
26%
22%9%
43%
RevenuebyProduct
EnbrelNeulastaAranespOtherProducts
HistoryVentureCapital
Startup
IPOandEPOGEN
$1Bsales
AcquiresENBREL
Beginsbiosimilardevelopment
1980|1983|1992|2002|2011
WhatistheSecretSauce?
WhatistheSecretSauce?
• Patents
WhatistheSecretSauce?
• Patents• R&Dtalent
WhatistheSecretSauce?
• Patents• R&Dtalent• Manufacturing
BrandedCompetitors(Enbrel)
PrioritizesBiotechnology
NoFDABiosimilars
DrugName Enbrel Humira Infliximab Rituximab
PercentTotalSales 26% 61% 21% 24%
Outlook:Neutral
Outlook:Neutral
+ Upcomingdrugpipeline
Outlook:Neutral
+ Upcomingdrugpipeline+/- Politicalclimate
Outlook:Neutral
+ Upcomingdrugpipeline+/- Politicalclimate- Patentexpiration
Questions
Referenceshttp://www.amgen.com/about/quick-facts/
http://www.amgenhistory.com
http://www.amgenbiosimilars.com/
https://en.wikipedia.org/wiki/List_of_largest_selling_pharmaceutical_products
https://www.nytimes.com/2016/07/16/business/makers-of-humira-and-enbrel-using-new-drug-patents-to-delay-generic-versions.html?_r=0
http://investors.abbvie.com/
https://www.jnj.com
http://www.roche.com/investors.htm
